the lilly mdr-tb partnership

The Lilly MDR-TB PartnershipCreating a sustainable strategy for combating a global public health pandemic

Increasing Corporate Engagement on Tuberculosis

Metropolitan Auditorium, Cape Town, 23.02.2010

2

Since 2003, Lilly has lead a comprehensive approach to fighting MDR-TB through

Awareness and Prevention

Treatment, Training and Surveillance

ResearchTransferring Technology

Community Support and Patient Advocacy

Reaching patients throughout the world

360° Approach: Partnership Overview

3

International Organizations and NGOs– International Federation of Red Cross & Red Crescent Societies – World Health Organization– Foundation for Professional Development– Centers for Disease Control– World Economic Forum– Global Business Coalition– UNICEF– USAID

Government Departments– Department of Health– Department of Public Service and Administration

Healthcare Provider Networks– International Hospital Federation– International Council of Nurses - DENOSA– World Medical Association - SAMA

Manufacturing Partners– Aspen Pharmacare (South Africa)– Hisun (China)– Shasun (India)– SIA/Biocom (Russia)

The Partners

4

World Economic Forum/GBC Develop a Global Awareness Toolkit for

Tuberculosis/MDR-TB in the workplace and disseminate through WEF/GBC member companies

Provide educational material targeting employees and in-plant healthcare staff

Pilot tested in India and adapt for other high-burden countries with large business communities

Conducted 3 workshops in South Africa in 2009 reaching over 60 participants from 33 companies

Workplace Toolkit

5

Transferring of Technology

Share Lilly’s specific and general manufacturing knowledge

Create self-sustaining centers of manufacturing excellence capable of providing additional products and employment

Support reliable generic producers to ensure expanded multi-source availability of the two drugs

Offer manufacturing firms in MDR-TB “hot spots” the technology to produce capreomycin and cycloserine

Give training in GMPs and Good Business Practices

Provide 10 full-time Lilly staff on-site over 4 years for technical assistance/training

Facilities in China and India receive technology to produce capreomycin and cycloserine API’s respectively, and South Africa and Russia produce both products

6

Technology successfully transferred to “hot spot” producers

7

THANK YOU!!!

8

Thank You!

Dr Osborn MahanjanaCorporate Affairs DirectorLilly MDR-TB Partnershipmahanjanaos@lilly.com South Africa

www.lilly.comwww.lillymdr-tb.com